Global

Sep 20, 2019

Periodic update on transaction details related to Philips’ share repurchases

Amsterdam, the NetherlandsRoyal Philips (NYSE: PHG, AEX: PHIA) today reported that in the period from September 13, 2019 up to and including September 19, 2019 a total of 173,381 of its own common shares were repurchased, with a weighted average purchase price of EUR 43.68. These repurchases were made under the repurchase program for capital reduction purposes, which was announced on January 29, 2019. Further details can be found via this link.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Click here to read moreClick here to read less

Topics

Contacts

Ben Zwirs

Ben Zwirs

Philips Global Press Office

Tel: +31 6 1521 3446

You are about to visit a Philips global content page

Continue
Ksenija Gonciarenko

Ksenija Gonciarenko

Philips Investor Relations

Tel: +31 20 59 77055

You are about to visit a Philips global content page

Continue

Press releases

Get our press releases by e-mail

You are about to visit a Philips global content page

Continue

Share on social media

  • https://www.philips.com/a-w/about/news/archive/standard/news/press/2019/20190920-periodic-update-on-transaction-details-related-to-philips-share-repurchases.html Link copied

You are about to visit a Philips global content page

Continue

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.